TY  - GEN
AU  - Isakov,Vasily
AU  - Paduta,Dzmitry
AU  - Viani,Rolando M
AU  - Enejosa,Jeffrey V
AU  - Pasechnikov,Viktor
AU  - Znoyko,Olga
AU  - Ogurtsov,Pavel
AU  - Bogomolov,Pavel O
AU  - Maevskaya,Marina V
AU  - Chen,Xiaotian
AU  - Shulman,Nancy S
TI  - Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)
SN  - 1473-5687
PY  - 2018///1126
KW  - 2-Naphthylamine
KW  - Adult
KW  - Aged
KW  - Anilides
KW  - adverse effects
KW  - Antiviral Agents
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Combinations
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - drug effects
KW  - Hepatitis C, Chronic
KW  - complications
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Liver Cirrhosis
KW  - diagnosis
KW  - Macrocyclic Compounds
KW  - Male
KW  - Middle Aged
KW  - Proline
KW  - analogs & derivatives
KW  - Republic of Belarus
KW  - Ribavirin
KW  - Ritonavir
KW  - Russia
KW  - Sulfonamides
KW  - Sustained Virologic Response
KW  - Time Factors
KW  - Treatment Outcome
KW  - Uracil
KW  - Valine
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
UR  - https://doi.org/10.1097/MEG.0000000000001166
ER  -